Nicolas Duverger
Pasteur Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nicolas Duverger.
Arteriosclerosis, Thrombosis, and Vascular Biology | 1993
Nicolas Duverger; Nordine Ghalim; G Ailhaud; Armin Steinmetz; Jean-Charles Fruchart; Graciela Castro
Apolipoprotein (apo) A-IV has been proposed to play a role in reverse cholesterol transport. ApoA-IV-containing lipoprotein particles (A-IVLp) were isolated from human plasma and interstitial fluid and characterized by immunoaffinity chromatography. Two major A-IVLp subpopulations, lipoprotein particles containing apoA-IV with apoA-I (LpA-I:A-IV) and lipoprotein particles containing apoA-IV without apoA-I (LpA-IV), were identified. The larger subpopulation of A-IVLp is the LpA-IV that represents 70% (protein mass) of the initial particles. Only 5.8% of apoA-IV was recovered in the retained fraction after affinity chromatography with an anti-apoA-I immunosorbent. ApoA-I, apoA-II, apoA-IV, apoB, apoC-III, apoD, apoE, apoH, lecithin: cholesterol acyltransferase (LCAT), cholesteryl ester transfer (CET) protein, proline-rich protein, and a protein of Mr 59,000 were detected in the A-IVLp. These particles contain more than 20% triglycerides (lipid mass). ApoA-IV-containing particles that were isolated from plasma are heterogeneous in size, consisting of two major populations with Stokes diameters of 10.3 nm and 9.3 nm. Both subpopulations of A-IVLp contain LCAT and CET activities and promote cholesterol efflux from cholesterol-preloaded adipose cells. These data support the hypothesis that A-IVLp particles may be involved in reverse cholesterol transport.
Biochimica et Biophysica Acta | 1994
Nicolas Duverger; Nordine Ghalim; Nathalie Theret; Jean Charles Fruchart; Graciela Castro
In order to investigate the relationship of lipid and apolipoprotein composition to cholesterol esterification in lipoproteins containing apolipoprotein (apo) A-IV, apo A-containing lipoprotein particles were isolated from fresh human plasma using a system of sequential immunoaffinity chromatography. Plasma was first depleted of apo B- and apo E-containing lipoproteins. Four major subpopulations of apo A-containing lipoprotein particles were separated: Lp A-I, Lp A-I: A-II, Lp A-IV and Lp A-I: A-IV: A-II. Lp A-IV and Lp A-I: A-IV: A-II contained less total lipid, less cholesterol and more triacylglycerol than Lp A-I and Lp A-I: A-II. Lp A-IV and Lp A-I: A-IV: A-II contained more sphingomyelin and less phosphatidylcholine than Lp A-I and Lp A-I: A-II and were richer in (16:0 + 18:0) saturated fatty acids. Among these isolated lipoprotein particles, Lp A-IV contained the highest lecithin: cholesterol acyltransferase (LCAT) activity per micrograms of protein. Cholesterol esterification rates were 2.6 +/- 0.5, 5.3 +/- 0.4 and 0.8 +/- 0.2 mumol of cholesterol per hour per mg of lipoproteins for Lp A-IV, Lp A-I and Lp A-I: A-II, respectively. The apolipoprotein and lipid composition and LCAT activity of Lp A-IV suggest that this lipoprotein may be a source of cholesterol esterification in plasma.
Biochimica et Biophysica Acta | 1993
Philippe Duchateau; Daniel J. Rader; Nicolas Duverger; Nathalie Theret; C. De Geitere; H.B. Brewer; Jean-Charles Fruchart; Graciela Castro
Tangier disease (TD) is characterized by extremely low plasma levels of HDL, apoA-I and apoA-II due to very rapid catabolism. However, the risk of premature coronary heart disease (CHD) is not markedly increased in TD. In order to gain insight into reverse cholesterol transport in TD, we isolated LpA-I, LpA-I:A-II, LpA-II and LpA-IV particles from fasting plasma of 5 TD patients. LpA-I composition was similar to control LpA-I, but TD LpA-I had more LCAT and CETP activity (respectively, 0.35 +/- 0.14 and 0.14 +/- 0.04 mumol of cholesterol esterified/h/micrograms of protein, and 7 +/- 2.5 and 1.4 +/- 0.3 mumol of cholesteryl ester transferred/h/micrograms of protein). In contrast, TD LpA-I:A-II had abnormal composition, with a low molar ratio of apoA-I to apoA-II (0.2-1.33). In addition, LpA-I:A-II in TD contained a substantial amount of apoA-IV compared with control, making this particle an LpA-I:A-II:A-IV complex. LpA-I:A-II from normal plasma do not promote cholesterol efflux from adipocytes cells, whereas TD LpA-I:A-II:A-IV complexes promoted cholesterol efflux from these cells. Moreover LpA-I:A-II:A-IV complexes have more LCAT and CETP activity than control (respectively 1.2 +/- 0.16 and 0.05 +/- 0.01 mumol of cholesterol esterified/h/micrograms of protein and, 41 +/- 3.7 and 1 +/- 0.4 mumol of cholesteryl ester transferred/h/micrograms of protein). The LpA-II particle in TD represented in fact an LpA-II:A-IV complex (75% mol apoA-II and 22% mol apoA-IV).(ABSTRACT TRUNCATED AT 250 WORDS)
Advances in Experimental Medicine and Biology | 1990
Nicolas Duverger; Nordine Ghalim; Nathalie Theret; Philippe Duchateau; Gustave Aguie; Gérard Ailhaud; Graciela Castro; Jean-Charles Fruchart
Many epidemiological studies have indicated that the plasma level of high density lipoproteins (HDL) is inversely correlated with the risk for coronary artery disease1. It has been hypothesized that HDL exerts this protective effect by the “reverse” transport of excess cholesterol from peripheral tissues to the liver2.
Biochemistry | 1993
Nicolas Duverger; Daniel J. Rader; Philippe Duchateau; Jean-Charles Fruchart; Graciela Castro; H B Brewer
FEBS Journal | 1991
Nicolas Duverger; Anne Murry-Brelier; Martine Latta; Soline Reboul; Graciela Castro; Jean-François Mayaux; Jean-Charles Fruchart; John M. Taylor; Armin Steinmetz; Patrice Denefle
Archive | 2002
Nicolas Duverger; Didier Branellec; Nathalie Aubailly; Glenda Bilder; Jeffrey Bostwick
Archive | 2002
Nicolas Duverger; Didier Branellec; Glenda Bilder; Jeffrey Bostwick; Nathalie Aubailly
Archive | 1996
Patrice Denefle; Nicolas Duverger
Archive | 2002
Nicolas Duverger; Didier Branellec; Glenda Bilder; Jeffrey Bostwick; Nathalie Aubailly